Проблема инфицирования эндодонта: современный взгляд на микробную биопленку (обзор литературы)
Abstract
Bacterial biofilm formation is the prevailing microbial lifestyle in natural and manmade environments and occurs on all
surface types. Biofilm formation develops in several phases and is influenced by various parameters, both environmental and
inherent to the attaching cell. Biofilms also serve as protective niches for particular pathogens when outside a host. Although
it is accepted that biofilms are ubiquitous in nature, the significance of biofilms in clinical settings, especially with regard to
their role in medical-related infections, is often underestimated. It has been found that several aspects of human pathogenesis
within a clinical context are directly related to biofilm development. Various types of surfaces in clinical settings are prone to
biofilm development and an increased risk of disease may be a direct consequence of their formation. This review describes
the process of biofilm formation, highlights the importance of bacterial associations with surfaces in clinical settings and describes
various methods for biofilm visualization and control.
Presented here are the current problems related to bacterium biofilms; current concepts of biofilm formation, persistence,
and interactions with the host immune system; and emerging technologies for controlling medical biofilms.
surface types. Biofilm formation develops in several phases and is influenced by various parameters, both environmental and
inherent to the attaching cell. Biofilms also serve as protective niches for particular pathogens when outside a host. Although
it is accepted that biofilms are ubiquitous in nature, the significance of biofilms in clinical settings, especially with regard to
their role in medical-related infections, is often underestimated. It has been found that several aspects of human pathogenesis
within a clinical context are directly related to biofilm development. Various types of surfaces in clinical settings are prone to
biofilm development and an increased risk of disease may be a direct consequence of their formation. This review describes
the process of biofilm formation, highlights the importance of bacterial associations with surfaces in clinical settings and describes
various methods for biofilm visualization and control.
Presented here are the current problems related to bacterium biofilms; current concepts of biofilm formation, persistence,
and interactions with the host immune system; and emerging technologies for controlling medical biofilms.
About the Authors
Л. Дмитриева
ФПДО ГОУ ВПО МГМСУ
Russian Federation
Russian Federation
К. Гуревич
МГМСУ
Russian Federation
Russian Federation
Л. Теблоева
ФПДО ГОУ ВПО МГМСУ
Russian Federation
Russian Federation
З. Ревазова
ФПДО ГОУ ВПО МГМСУ
Russian Federation
Russian Federation
References
1. Kinney J. S., Ramseier C. A., Giannobile W. V. Oral fluid-based biomarkers of alveolar bone loss in periodontitis // Ann N Y Acad Sci. 2007. №1098. Р. 230-251.
2. Albandar J. M. Periodontal diseases in North America // Periodontol. 2000-2002. №29. Р. 31-69.
3. Woodward J. K., Holen I., Coleman R. E., Buttle D. J. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer // Bone. 2007. №41. Р. 912-927.
4. Pussinen P. J., Paju S., Mantyla P., Sorsa T. Serum microbial- and host-derived markers of periodontal diseases: A review // Curr Med Chem. 2007. №14. Р. 2402-2412.
5. Keller U., Doucet A., Overall C. M. Protease research in the era of systems biology // Biol Chem. 2007. №388. P. 1159-1162.
6. Ra H. J., Parks W. C. Control of matrix metalloproteinase catalytic activity // Matrix Biol. 2007. №26. P. 587-596.
7. Tester A. M., Cox J. H., Connor A. R. et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity // PLoS ONE. 2007. №2. P. 312.
8. Gill S. E., Parks W. C. Metalloproteinases and their inhibitors: Regulators of wound healing // Int J Biochem Cell Biol. 2007. №40. P. 1334-1347.
9. Lopez-Otin C., Matrisian L. M. Emerging roles of proteases in tu mour suppression // Nat Rev Cancer.
10. №7. P. 800-808.
11. Sorsa T., Tjäderhane L., Konttinen Y. T. et al. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation // Ann Med. 2006. №38. P. 306-321.
12. Golub L. M., Lee H. M., Greenwald R. A. et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis // Inflamm Res. 1997. №46. P. 310-319.
13. Herr A. E., Hatch A. V., Giannobile W. V. et al. Integrated microfluidic platform for oral diagnostics // Ann N Y Acad Sci. 2007. №1098. P. 362-374.
14. Herr A. E., Hatch A. V., Throckmorton D. J. et al. Microfluidic immunoassays as rapid salivabased clinical diagnostics // Proc Natl Acad Sci USA. 2007. №104. P. 5268-5273.
15. Kinane D. F., Darby I. B., Said S. et al. Changes in gingival crevicular fluid matrix metalloproteinase-8 levels during periodontal treatment and maintenance // J Periodontal Res. 2003. №38. P. 400-404.
16. Kirkwood K. L., Cirelli J. A., Rogers J. E., Giannobile W. V. Novel host response therapeutic approaches to treat periodontal diseases // Periodontol 2000-2007. №43. P. 294-315.
17. Golub L. M., Payne J. B., Reinhardt R. A., Nieman G. Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical two-hit model // J Dent Res. 2006. №85. P. 102-105.
18. Golub L. M., Suomalainen K., Sorsa T. Host modulation with tetracyclines and their chemically modified analogues // Curr Opin Dent. 1992. №2. P. 80-90.
19. Williams R. C. Periodontal disease // N Engl J Med. 1990. №322. P. 373-382.
20. Olsen N. J., Stein C. M. New drugs for rheumatoid arthritis // N Engl J Med 2004. №350. P. 2167-2179.
21. Ashley R. A. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD Clinical Research Team // Ann N Y Acad Sci. 1999. №878. P. 335-346.
22. Ciancio S., Ashley R. Safety and efficacy of sub-antimicrobialdose doxycycline therapy in patients with adult periodontitis // Adv Dent Res. 1998. №12. P. 27-31.
23. Caton J. G., Ciancio S. G., Blieden T. M. et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis // J Periodontol. 2000. №71. P. 521-532.
24. Reddy M. S., Geurs N. C., Gunsolley J. C. Periodontal host modulation with antiproteinase, anti- inflammatory, and bone-sparing agents. A systematic review // Ann Periodontol. 2003. №8. P. 12-37.
25. Preshaw P. M., Novak M. J., Mellonig J. et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease // J Periodontol. 2008. №79. P. 440-452.
26. Gapski R., Barr J. L., Sarment D. P., Layher M. G., Socransky S. S., Giannobile W. V. Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: A proof of concept trial // J Periodontol. 2004. №75. P. 441-452.
27. Payne J. B., Stoner J. A., Nummikoski P. V, et al. Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women // J Clin Periodontol. 2007. №34. P. 776-787.
28. Reinhardt R. A., Stoner J. A., Golub L. M. et al. Efficacy of sub-antimicrobial dose doxycycline in post-menopausal women: Clinical outcomes // J Clin Periodontol. 2007. №34. P. 768-775.
29. Golub L. M, Lee H. M., Stoner J. A. et al. Subantimicrobialdose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women // J Periodontol. 2008. №79. P. 1409-1418.
30. Nuti E., Tuccinardi T., Rossello A. Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors // Curr Pharm Des. 2007. №13. P. 2087-2100.
31. Tenenbaum H. C., Shelemay A., Girard B., Zohar R., Fritz P. C. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses // J Periodontol. 2002. №73. P. 813-822.
32. Kamel H. K. Update on osteoporosis management in longterm care: Focus on bisphosphonates // J Am Med Dir Assoc. 2007. №8. P. 434-440.
33. Jeffcoat M. K., Reddy M. S. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z., Norton L. A., eds. Biological mechanisms of tooth movement and craniofacial adaptation. Vol. 1. Cambridge, MA // Harvard Society for the Advancement of Orthodontics. 1996. P. 365-373.
34. Rocha M., Nava L. E., Vázquez de la Torre C., Sánchez-Marin F., Garay-Sevilla M. E., Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: A randomized, placebo- controlled trial // J Periodontol. 2001. №72. P. 204-209.
35. Takaishi Y., Miki T., Nishizawa Y., Morii H. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: Report of four cases // J Int Med Res. 2001. №29. P. 355-365.
36. Lane N., Armitage G. C., Loomer P. et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12-month, randomized, placebo-controlled study // J Periodontol. 2005. №76. P. 1113-1122.
37. Wang H. L., Weber D., Mc-Cauley L. K. Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report // J Periodontol. 2007. №78. P. 584-594.
38. Ficarra G., Beninati F., Rubino I. et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment // J Clin Periodontol. 2005. №32. P. 1123-1128.
39. Khosla S., Burr D., Cauley J. et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American society for bone and mineral research // J Bone Miner Res. 2007. №22. P. 1479-1491.
Review
For citations:
, , , . Endodontics Today. 2010;8(1):12-15. (In Russ.)
Email this article 